Table 3.
Detection rates by PSA levels, imaging modality, primary treatment and patient categories.
| Detection rates (%) | mpMRI | PET/MRI | ||
|---|---|---|---|---|
| Score 2+3 | Score 3 | Score 2+3 | Score 3 | |
| Overall | 41.7% | 22.6% | 39.3% | 28.6% |
| PSA level | ||||
| PSA≥1 ng/mL PSA<1ng/mL p-value, PSA subgroup comparison Adjusted p-value |
55.6% 31.3% (0.025) 0.025 |
36.1% 12.5% (0.01) 0.013 |
55.6% 27.1% (0.008) 0.013 |
44.4% 16.7% (0.005) 0.013 |
| PSAdt* | ||||
| PSAdt<6months PSAdt≥6 months p-value, PSAdt subgroup comparison |
41.2% 35% (0.658) |
23.5% 20% (0.765) |
47.1% 32.5% (0.297) |
35.3% 20% (0.220) |
| Primary treatment | ||||
| RP EBRT p-value, primary treatment subgroup comparison Adjusted p-value |
35.2% 76.9% (0,005) 0.02 |
18.3% 46.2% (0.027) 0.028 |
33.8% 69.2% (0.016) 0.028 |
23.9% 53.9% (0.028) 0.028 |
| Patient category | ||||
| PSA persistence EAU Low-Risk BCR EAU High-Risk BCR BCR unassigned p-value, patient category comparison Adjusted p-value |
38.9% 33.3% 48.7% 33.3% (0.653) 0.653 |
27.8% 0% 30.8% 13.3% (0.035) 0.070 |
38.9% 25.0% 48.7% 26.7% (0.323) 0.431 |
38.9% 0% 38.5% 13.3% (0.005) 0.020 |
p-values and adjusted p-values are from chi-square tests for evaluation of differences in detection rates between subgroups. *In patients for whom PSAdt could be calculated (n = 57). The group BCR unassigned are patients with biochemical recurrence that could not be assigned to one of the EAU risk groups due to lack of PSAdt.